This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Zynex (ZYXI) is likely to maintain the current high on a number of favorable factors.
Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System
by Zacks Equity Research
Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.
Medtronic's All Business Lines Grow Despite Cost Concerns
by Zacks Equity Research
Within Diabetes group, Medtronic (MDT) is seeing a strong adoption of the Guardian Connect Smart CGM system.
Boston Scientific (BSX) Upbeat on Results of EVOLVE Study
by Zacks Equity Research
Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.
NuVasive Announces Innovations in Robotics Spine Surgery Line
by Zacks Equity Research
NuVasive (NUVA) aims to speed up the adoption of less invasive spine surgery through robotics.
Align Gains on Innovation Despite Poor Case Shipment in China
by Zacks Equity Research
Align Technology (ALGN) succeeds in consecutively delivering a solid spurt in Invisalign Technology volumes across the company's entire clientele.
Natera (NTRA) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Natera (NTRA) is likely to maintain the current high on a number of favorable factors.
FDA Nods to Medtronic's (MDT) New Age Evolut PRO+ TAVR
by Zacks Equity Research
This latest FDA approval of Medtronic's (MDT) Evolut PRO+ follows the last month's nod from the regulatory body for the Evolut TAVR system with regard to expanded indication.
Insulet Receives FDA Approval for ACE Pump Implementation
by Zacks Equity Research
FDA's approval will enable Insulet (PODD) to boost its insulin management business.
Bruker (BRKR) Enters Into Alliance With Murdoch University
by Zacks Equity Research
Bruker's (BRKR) collaboration with Murdoch University will support International Centre of Excellence in metabolic phenotyping.
Neogen Forms Partnership With IGS to Enhance Beef Profile
by Zacks Equity Research
Neogen (NEOG), through the IGS partnership, aims to help cattle producers choose better cattle and enhance their productivity.
Medtronic Receives European Nod for Glucose Monitoring System
by Zacks Equity Research
Medtronic (MDT) plans to upgrade diabetes care by combining technical advancement with better user experience.
Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line
by Zacks Equity Research
Zimmer Biomet's (ZBH) JuggerStitch claims to offer a less invasive, all-suture, knotless approach to meniscal repair procedures.
Abbott Receives European Nod for Pediatric Heart Devices
by Zacks Equity Research
Abbott (ABT) aims to offer better treatment options for the most vulnerable patient population.
Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement
by Zacks Equity Research
With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.
Medtronic (MDT) Earns Dow Jones Sustainability Recognition
by Zacks Equity Research
Medtronic's (MDT) strong ESG practices facilitate inclusion in the North American Dow Jones Sustainability Index.
Walgreens' Retail Pharmacy Stays Firm Amid Reimbursement Woes
by Zacks Equity Research
Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.
CryoLife Enters Agreement With Endospan for Aortic Stent
by Zacks Equity Research
CryoLife (CRY) eyes to expand the portfolio of aortic care, with endovascular stent graft system.
Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring
by Zacks Equity Research
Baxter (BAX) expects this deal to remain neutral to its earnings in 2019 and 2020.
Zimmer Biomet (ZBH) Launches Persona Revision for Knee Care
by Zacks Equity Research
Zimmer Biomet (ZBH) prepares for the commercial launch of improvised knee replacement procedures through its flagship program, Persona Revision Knee System.
LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod
by Zacks Equity Research
LivaNova (LIVN) is aiming to reach out to more patients, with improved enrollment program.
Neurotrope Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Neurotrope has been struggling lately, but the selling pressure may be coming to an end soon.
Is the Options Market Predicting a Spike in Neurotrope (NTRP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Neurotrope (NTRP) stock based on the movements in the options market lately.
Neurotrope Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Neurotrope, Inc. (NTRP) has been struggling lately, but the selling pressure may be coming to an end soon.
Why Is Neurotrope (NTRP) Stock Crashing Today?
by Ryan McQueeney
Shares of Neurotrope Bioscience (NTRP) opened more than 46% lower on Monday after the company released the results of its clinical trial for bryostatin, a drug candidate for patients with moderate to severe Alzheimer's.